Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure
Almost half of the world ’s population has no or limited access to diagnosticsThis situation is especially acute in low- and middle-income countries (LMICs) where diagnostics plays a critical role for treating and containing the spread of infectious diseases such as Tuberculosis (TB) and HIVNew partnership between Roche and the Global Fund supports low- and middle-income countries in broadening access to diagnostics, helping millions of previously undiagnosed people with TB and HIV get diagnosed and eventually treatedBasel, 12 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY), through its Global Access Program, and The Globa...
Source: Roche Media News - May 12, 2022 Category: Pharmaceuticals Source Type: news

Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure
Almost half of the world ’s population has no or limited access to diagnosticsThis situation is especially acute in low- and middle-income countries (LMICs) where diagnostics plays a critical role for treating and containing the spread of infectious diseases such as Tuberculosis (TB) and HIVNew partnership between Roche and the Global Fund supports low- and middle-income countries in broadening access to diagnostics, helping millions of previously undiagnosed people with TB and HIV get diagnosed and eventually treatedBasel, 12 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY), through its Global Access Program, and The Globa...
Source: Roche Investor Update - May 12, 2022 Category: Pharmaceuticals Source Type: news

Janssen Discontinues Collaboration and License Agreements with Bavarian Nordic in Hepatitis B and Human Papillomavirus
NEW BRUNSWICK, NJ, May 9, 2022 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the termination of its collaboration and license agreements with Bavarian Nordic that leverage Bavarian Nordic’s MVA-BN® (Modified Vaccinia Ankara - Bavarian Nordic) technology to develop potential vaccines against the hepatitis B virus and human papillomaviruses. Janssen remains committed to its strong collaboration with Bavarian Nordic in the quest to prevent and cure infectious diseases – with collaborations in HIV and Ebola still ongoing.No clinical studies in hepatitis B have been initiated by Janssen ut...
Source: Johnson and Johnson - May 9, 2022 Category: Pharmaceuticals Source Type: news

Abbott Obtains FDA Clearance for First Test that Simultaneously Detects Four Common Sexually Transmitted Infections (STIs) as Cases are on the Rise
Abbott's multiplex test runs on its most advanced molecular PCR platform, the Alinity™ m system, which provides fast results in high volumes – detecting four infections simultaneously Test provides a critically important tool as people return to regular... Diagnostics, FDA Abbott, Alinity m, Hepatitis C, Hepatitis B, HIV (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 4, 2022 Category: Pharmaceuticals Source Type: news

Why I Recommend Hepatitis B Vaccination to All My Patients Why I Recommend Hepatitis B Vaccination to All My Patients
New age-based hepatitis B vaccine recommendations and available vaccine products are reviewed by Dr Sandra Fryhofer.Medscape Internal Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - May 3, 2022 Category: Infectious Diseases Tags: Internal Medicine Commentary Source Type: news

Lupin gets USFDA nod to market drug used to treat chronic hepatitis B
The company has received tentative approval from the United States Food and Drug Administration (FDA) for its abbreviated new drug application for Tenofovir Alafenamide tablets (25 mg), Lupin said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 18, 2022 Category: Pharmaceuticals Source Type: news

Tenofovir vs. Entecavir Therapy in HBV: Long-term Renal Safety Tenofovir vs. Entecavir Therapy in HBV: Long-term Renal Safety
Do tenofovir and entecavir differ in their long-term impact on renal function in patients with hepatitis B?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 11, 2022 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

CDC Recommends Hep B Vaccination for Most Adults CDC Recommends Hep B Vaccination for Most Adults
Faced with an increasing incidence of hepatitis B infection, the Centers for Disease Control and Prevention expanded its vaccination recommendation to include most adults.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - April 2, 2022 Category: Infectious Diseases Tags: Gastroenterology News Source Type: news

Risk for Acute MI Not Increased With Two-Dose HepB-CpG Vaccine
FRIDAY, April 1, 2022 -- The rate of type 1 acute myocardial infarction (MI) is not increased with receipt of the two-dose hepatitis B vaccine with a cytosine phosphoguanine adjuvant (HepB-CpG vaccine) versus the three-dose hepatitis B vaccine with... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 1, 2022 Category: Pharmaceuticals Source Type: news

Universal HepB Vaccination Recommended for Adults Age 19 to 59
THURSDAY, March 31, 2022 -- Hepatitis B (HepB) vaccination should be administered to adults aged 19 to 59 years and to those aged 60 years or older with risk factors for HepB, according to updated recommendations published in the April 1 issue of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 31, 2022 Category: Pharmaceuticals Source Type: news

Universal Hepatitis B Vaccination in Adults Aged 19-59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022
This report describes updated hepatitis B vaccination recommendations from the Advisory Committee on Immunization Practices. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - March 31, 2022 Category: American Health Tags: Advisory Committee on Immunization Practices (ACIP) Hepatitis B MMWR Morbidity & Mortality Weekly Report Source Type: news

Reassuring Data on Two-Dose Hep B Vaccine, Risk of Acute MI
(MedPage Today) -- There was no higher risk of heart attack for recipients of the two-dose hepatitis B cytosine phosphoguanine adjuvant vaccine (Heplisav-B) compared to the three-dose hepatitis B vaccine with an aluminum hydroxide adjuvant (Engerix... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - March 28, 2022 Category: Gastroenterology Source Type: news

After patient hospitalized, Peninsula drug developer stops 2nd chronic hepatitis B program this year
The stock of the 93-employee company, which was over $34 a share in the past year, is trading below $3. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 22, 2022 Category: American Health Authors: Ron Leuty Source Type: news

Ghana: Over 200 Vaccinated Against Hepatitis B in Wa Communities
[Ghanaian Times] Wa -- More than 200 people have been vaccinated against Hepatitis B in the last 10 months in six communities in the Wa Municipality and the Wa East District of the Upper West Region. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - March 18, 2022 Category: African Health Source Type: news

EMA Recommends PreHevbri Hepatitis B Vaccine for Approval EMA Recommends PreHevbri Hepatitis B Vaccine for Approval
The three-antigen hepatitis B vaccine received approval from the FDA in November 2021.International Approvals (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - March 1, 2022 Category: Infectious Diseases Tags: Infectious Diseases News Alert Source Type: news